Skip to main content
MedPathMedPath Home
Clinical Trials/NCT07415135
NCT07415135
Not yet recruiting
Phase 2

Phase Ⅱ Clinical Study on the Safety and Efficacy of PSMA-Targeted Fluorescent Contrast Agent DGPR1008 for Intraoperative Imaging in Robot-Assisted Radical Prostatectomy

Zhu Yinjie0 sites18 target enrollmentStarted: March 1, 2026Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Interventions0.02 mg/kg of DGPR1008 Injection was administered 24 hours before surgery0.04 mg/kg of DGPR1008 Injection was administered 24 hours before surgery0.06 mg/kg of DGPR1008 Injection was administered 24 hours before surgery

Overview

Phase
Phase 2
Status
Not yet recruiting
Sponsor
Zhu Yinjie
Enrollment
18
Primary Endpoint
To evaluate the sensitivity (true positive rate, TP/(TP+FN)), specificity (true negative rate, TN/(TN+FP)), false positive rate (FP/(FP+TN)) and false negative rate (FN/(FN+TP)) of DGPR1008 for detecting prostate cancer tissues via near-infrared fluoresc
OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Overview

Brief Summary

This study is a single-center, single-arm, open-label exploratory study to evaluate the safety and efficacy of fluorescent imaging combined with a robotic surgical control system for robot-assisted radical prostatectomy.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Sequential
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Subjects with pathologically confirmed prostate cancer via preoperative prostate core needle biopsy who are scheduled to undergo robot-assisted radical prostatectomy (RARP).
  • •Subjects must provide informed consent for the trial prior to enrollment, with a full understanding of the trial content, procedures and potential adverse events; they must be able to communicate effectively with investigators, comply with the trial protocol to complete the entire study, and voluntarily sign a written informed consent form.
  • •Male adult subjects aged 18 years or older (inclusive).
  • •Gleason total score ≥7, or radiological findings (transrectal ultrasound (TRUS) and/or prostate magnetic resonance imaging (MRI), computed tomography (CT) or prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT)) indicating clinical stage ≥T
  • •No hepatic or renal impairment: Hepatic function: Total bilirubin ≤2 × upper limit of normal (ULN) (except for Gilbert's syndrome), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤3 × ULN; Renal function: Creatinine clearance rate ≥50 mL/min/1.73 m² (calculated via the simplified MDRD equation).
  • •Subjects judged by the investigator to have no definite surgical contraindications and to be suitable for robot-assisted radical prostatectomy (RARP).
  • •Subjects and their partners/spouses must agree to have no childbearing or sperm donation plans from the screening period to 3 months after the trial completion, and voluntarily adopt effective contraceptive measures.

Exclusion Criteria

  • •Subjects with an allergic diathesis (e.g., a known history of hypersensitivity to two or more drugs), a predisposition to allergic symptoms such as rashes or urticaria, or a known hypersensitivity to the study drug (including its ingredients).
  • •Subjects with clinically significant abnormal findings in screening tests that are judged by the investigator to affect the study; or those with comorbidities that pose a serious risk to subject safety or interfere with study completion (except for subjects whose conditions are judged by the investigator to be stable for enrollment).
  • •Subjects who have participated in other clinical trials and received investigational drugs or medical devices within 1 month prior to the administration of the study drug.
  • •Subjects who have received neoadjuvant therapy, radiotherapy, focal ablation therapy, hormonal therapy, androgen deprivation therapy, or other such treatments in the past 6 months.
  • •Subjects who are judged by the investigator to be ineligible for the study due to other circumstances.

Arms & Interventions

0.02mg/kg DGPR1008 Injection Dose Group 1 (n=4~10)

Experimental

0.02mg/kg

Intervention: 0.02 mg/kg of DGPR1008 Injection was administered 24 hours before surgery (Drug)

0.04mg/kg DGPR1008 Injection Dose Group 1 (n=4~10)

Experimental

0.04mg/kg

Intervention: 0.04 mg/kg of DGPR1008 Injection was administered 24 hours before surgery (Drug)

0.06mg/kg DGPR1008 Injection Dose Group 1 (n=4~10)

Experimental

0.06mg/kg

Intervention: 0.06 mg/kg of DGPR1008 Injection was administered 24 hours before surgery (Drug)

Outcomes

Primary Outcomes

To evaluate the sensitivity (true positive rate, TP/(TP+FN)), specificity (true negative rate, TN/(TN+FP)), false positive rate (FP/(FP+TN)) and false negative rate (FN/(FN+TP)) of DGPR1008 for detecting prostate cancer tissues via near-infrared fluoresc

Time Frame: 7 days after administration

To evaluate the proportion of additionally resected tissues (due to fluorescent signals in tumor beds identified by near-infrared fluorescent imaging (NIR)) that are assessed as tumor-positive by histopathological examination after radical prostatectomy.

Time Frame: 7 days after administration

Secondary Outcomes

  • To evaluate the proportion of subjects with a positive surgical margin (PSM) of ≥1 as assessed by histopathological examination after radical prostatectomy.(7 days after administration)
  • Number of participants with Adverse events(7 days after administration)
  • To evaluate the Tumor-to-Background Ratio (TBR)(7 days after administration)

Investigators

Sponsor
Zhu Yinjie
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Zhu Yinjie

Clinical Professor

RenJi Hospital

Similar Trials

Recruiting
Phase 2
NWRD06 DNA Plasmid for HCC After Curative Resection.
NCT07324304Newish Technology (Beijing) Co., Ltd.30
Not yet recruiting
Not Applicable
A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer
NCT07283198Jiangsu Alphamab Biopharmaceuticals Co., Ltd160
Not yet recruiting
Not Applicable
Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
NCT07286292Institut de Recherches Internationales Servier (I.R.I.S.)10
Recruiting
Phase 2
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC
NCT07264816Sichuan Baili Pharmaceutical Co., Ltd.80
Not yet recruiting
Phase 2
Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma
NCT07314216Hunan Cancer Hospital15